Ductal Carcinoma in Situ (DCIS): Treatment & Decisions

DCIS stands for ductal carcinoma in situ. Abnormal cells have been found inside one of the milk ducts of the breast, and they have not broken through the wall of that duct into surrounding breast tissue. That containment is what "in situ" means, and it is why DCIS is called non-invasive and staged as stage 0, the earliest stage.

It is common: the National Cancer Institute estimates that about 20% to 25% of new breast cancer diagnoses in the United States each year are DCIS, and the American Cancer Society puts it at roughly 1 in 5.

The outlook is very good. NCI reports that more than 98% of people diagnosed with DCIS are alive five years later, and that DCIS is less likely to come back than invasive breast cancer. The American Cancer Society says nearly all women diagnosed at this stage can be cured.

Under a microscope, the cells look like cancer cells. That is why carcinoma is in the name, and why DCIS has a place inside breast cancer staging. The paperwork, the clinic and the insurance forms all use that word.

Trusted sources still describe DCIS in noticeably different words. NCI calls it noninvasive breast cancer, intraductal carcinoma or stage 0 breast cancer, and notes it may also be called precancer. The American Cancer Society calls it non-invasive or pre-invasive breast cancer.

That mixture of language arrives at the moment you least want ambiguity. Many people hear one word, cancer, and their mind goes straight to chemotherapy, to spread, to dying. The fear is understandable. What the word alone does not tell you is how contained the situation is; that comes from your pathology report. If the naming is what frightens you, say so to your team.

Most DCIS is found on a screening mammogram, before anything can be felt. On the image it usually shows up as calcifications, tiny white specks. A biopsy confirms the diagnosis, shows whether the cells have stayed inside the duct, and gives two things that shape every conversation after it: the grade, and whether the cells have hormone receptors.

Grade describes how abnormal the cells look and how quickly they are likely to grow. It is one factor a team weighs when discussing how much treatment to consider, but on its own it cannot say what will happen.

Margins matter after breast-conserving surgery. A pathologist checks the rim of normal tissue around what was removed. The American Cancer Society describes the goal as at least 2 mm of cancer-free tissue around it, to lower the chance of the DCIS returning in that breast. If the margin is not clear, more surgery may be offered, and if clear margins cannot be reached even then, mastectomy may be recommended.

Surgery. Breast-conserving surgery, or lumpectomy, removes the DCIS with a margin of surrounding tissue. Mastectomy removes the whole breast, and is usually recommended when the DCIS is large, when it is present in more than one separate area of the breast, or when clear margins cannot be achieved.

Radiation. Radiation is generally given after lumpectomy, to lower the risk of the DCIS coming back in the same breast. It may be left out for some people, such as older people or those with other serious health conditions, when the DCIS is small, low grade and removed with good margins.

Endocrine (hormone) therapy. If the DCIS has hormone receptors, tamoxifen or an aromatase inhibitor may be offered. The American Cancer Society reports that five years of this treatment can lower the risk of another DCIS or an invasive cancer developing in either breast.

Lymph nodes. Nodes are usually not removed when DCIS is treated with lumpectomy, though a sentinel lymph node biopsy is often done alongside mastectomy, or if invasive cancer turns up in the tissue removed.

One point recurs across the sources: studies followed for more than 20 years show that lumpectomy plus radiation gives the same survival as mastectomy. Choosing the smaller operation is not choosing a worse outcome.

Here is the honest problem at the centre of DCIS. NCI states that there is currently no way to tell which lesions found on screening mammograms will become invasive, and that this leaves people with DCIS facing a substantial risk of overdiagnosis and overtreatment. The American Cancer Society agrees there is no good way to know for sure. Some DCIS would become invasive. Some never would. Nobody can tell you today which one yours is.

Because of that uncertainty, treatment is offered to everyone, and some of it inevitably goes to people who would never have been harmed. Treatment carries its own costs: NCI has quoted Barry Kramer, then director of its Division of Cancer Prevention, noting that DCIS treatments carry potential harms, including complications of mastectomy and second cancers linked to radiation.

Researchers are testing whether some people can safely skip surgery. NCI reports that in a trial reported in 2024, people with low-risk DCIS who were actively monitored were no more likely to be diagnosed with invasive breast cancer after two years than people who had surgery with or without radiation, and that longer follow-up is needed to judge the long-term safety of forgoing surgery. Other trials are studying active surveillance with hormone therapy, and researchers are using artificial intelligence to try to identify which DCIS is likelier to progress. Outside a trial, monitoring instead of surgery is not standard care today.

Numbers narrow the question, but they cannot close it. More than one path leads to a good outcome, so the decision turns on what you weigh most: how you feel about surgery on your breast, weeks of daily radiation appointments, five years of endocrine therapy and its side effects, mammograms that make you hold your breath every year, living alongside a known unknown.

Some people are comfortable with the smallest reasonable treatment and close follow-up. Others find lingering uncertainty hard to live with and want the most definitive option open to them. Neither response is irrational, and neither is the right answer for everyone.

What helps is getting specific: ask what your grade, margins and receptor status say about your situation, what each option would change and what it would not, and whether a trial is open to you. You are allowed to hear the answers more than once before you decide.